What ICD‑10 code should be used to prescribe Blisovi 24 Fe (norethindrone acetate + ethinyl estradiol) for a reproductive‑age woman without contraindications?

ICD-10 Code for Prescribing Blisovi 24 Fe

For prescribing Blisovi 24 Fe (norethindrone acetate/ethinyl estradiol) oral contraceptive, use ICD-10 code Z30.011 (encounter for initial prescription of contraceptive pills) for new users or Z30.41 (encounter for surveillance of contraceptive pills) for established users.

Coding Framework

The appropriate ICD-10 code depends on whether this is an initial prescription or ongoing contraceptive management:

For New Prescriptions

• Z30.011 - Encounter for initial prescription of contraceptive pills
  • Use this code when prescribing Blisovi 24 Fe for the first time to a patient
  • Applies to patients switching from another contraceptive method to oral contraceptives

For Refills and Ongoing Management

• Z30.41 - Encounter for surveillance of contraceptive pills
  • Use this code for routine refills and follow-up visits
  • Applies to patients already established on oral contraceptive therapy

Additional Codes for Specific Indications

If prescribing Blisovi 24 Fe for non-contraceptive indications (though contraception is the FDA-approved indication 1), consider:

• N92.0 - Excessive and frequent menstruation with regular cycle (menorrhagia)
• N94.6 - Dysmenorrhea, unspecified (menstrual cramps)
• L70.0 - Acne vulgaris (if treating acne as secondary benefit)

Important Clinical Considerations

Contraindications to verify before prescribing (per FDA labeling 1):

• Women over 35 years who smoke (absolute contraindication)
• High risk of arterial or venous thrombotic disease
• Current or history of breast cancer
• Undiagnosed abnormal uterine bleeding
• Liver tumors or active liver disease
• Co-administration with certain Hepatitis C drug combinations

No examination required: According to the 2024 CDC guidelines, no pelvic examination, breast examination, or laboratory tests are required before initiating combined hormonal contraceptives in healthy women 2. This is a Class C recommendation - these examinations do not contribute substantially to safe and effective use.

Common Pitfalls to Avoid

1. Do not use diagnosis codes for conditions being prevented (e.g., Z30.09 for pregnancy prevention is less specific than Z30.011)
2. Do not require unnecessary testing - The 2024 CDC guidelines emphasize that CHCs can be initiated without physical examination in presumed healthy patients 2
3. BMI consideration - Note that efficacy in women with BMI >35 kg/m² has not been established 1, though this is not a contraindication

The Z30 code series is specifically designed for contraceptive management encounters and will ensure appropriate billing and documentation for this FDA-approved indication 1.